Insilico Medicine

AI for Accelerated Drug Discovery

New Territories, Massachusetts, Hong Kong

Drug Discovery/Development AI / ML PharmaTechPublic

Global clinical-stage biotechnology company powered by generative AI focused on drug discovery.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Insilico Medicine on @MedStartr Today Global clinical-stage biotechnology company powered by generative AI focused on drug discovery. #Fibrosis #Immunity #AgingRelatedDiseases #Pain #MuscleWasting #ObesityOverweight #AutoimmuneDiseases #InfectiousDiseases #CentralNervousSystemDisorders #MetabolicConditions #IdiopathicPulmonaryFibrosisIPF #CancerOncology #DrugDiscoveryDevelopment #AIML #PharmaTech #MedMo #MedStartrVentures

https://www.medstartr.ai/s/6miE6s4JHHU

Get Involved in Insilico Medicine

How We Help

Problem Statement

The high time and cost associated with traditional drug discovery and development processes.

Core Technology

generative AI

Key Differentiators

End-to-End Generative AI Platform (Pharma.AI covers entire workflow); Speed and Efficiency (reduces preclinical discovery timelines to 12-18 months, drugs to Phase I in under 30 months); First AI-Discovered and AI-Designed Drug in Clinical Trials (for idiopathic pulmonary fibrosis, currently in Phase II); Diversified Pipeline (over 30 assets, 10 IND clearances); Strategic Partnerships and Licensing (high-value out-licensing and collaborations); Pioneering AI Techniques (Alex Zhavoronkov pioneered GANs and RL for molecular structure generation, developing autonomous AI agent PandaClaw).

Clinical Focus

Cancer, fibrosis (idiopathic pulmonary fibrosis), immunity, central nervous system (CNS) diseases, infectious diseases, autoimmune diseases, aging-related diseases, pain, obesity, muscle wasting

Target Customers

Pharmaceutical companies, biotech companies, academic institutions

Product Stage

Company Info

Business Model: B2B, software licensing, therapeutic out-licensing
Founded: 2014
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: insilico.com/

Disease Areas

Fibrosis Immunity Aging-Related Diseases Pain Muscle Wasting Obesity & Overweight Autoimmune Disease Infectious Diseases Central Nervous System Disorders Metabolic Conditions Idiopathic Pulmonary Fibrosis (IPF)Cancer & Oncology

Technologies

Generative AIPandaOmicsChemistry42inClinicoGANs (Generative Adversarial Networks)PandaClaw (Autonomous AI Agent)Reinforcement LearningAI & Machine Learning

Clinical & IP

🔬

Clinical Validation

First AI-discovered and AI-designed drug for idiopathic pulmonary fibrosis in Phase II clinical trials; achieved 10 IND clearances for pipeline assets.

🌐Website

MedStartr Engagement Score

Too Big!

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Insilico Medicine?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.